{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:42:30Z","timestamp":1782459750321,"version":"3.54.5"},"reference-count":128,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020473","name":"BRIN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015689","name":"Institut Teknologi Bandung","doi-asserted-by":"publisher","award":["PN-6-06-2024"],"award-info":[{"award-number":["PN-6-06-2024"]}],"id":[{"id":"10.13039\/501100015689","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.aohep.2024.101533","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:25:15Z","timestamp":1723555515000},"page":"101533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-0500","authenticated-orcid":false,"given":"Patricia Gita","family":"Naully","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-8663","authenticated-orcid":false,"given":"Marselina Irasonia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustiningsih","family":"Agustiningsih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caecilia","family":"Sukowati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernawati Arifin","family":"Giri-Rachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2024.101533_bib0001","series-title":"Hepatitis b 2023","year":"2023"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0003","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/hep.23934","article-title":"Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options","volume":"52","author":"Jonas","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0004","first-page":"37","article-title":"Pediatric hepatitis B treatment","volume":"5","author":"Komatsu","year":"2017","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0005","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2012.03.036","article-title":"Chronic hepatitis B in children and adolescents","volume":"57","author":"Paganelli","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0006","first-page":"1401","article-title":"Chronic Hepatitis B therapies: challenges and opportunities","volume":"36","author":"Aguilar-Rubido","year":"2019","journal-title":"Biotecnol Apl"},{"key":"10.1016\/j.aohep.2024.101533_bib0007","series-title":"Global hepatitis report 2017","year":"2017"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0008","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Semin Immunopathol"},{"issue":"23","key":"10.1016\/j.aohep.2024.101533_bib0009","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.3748\/wjg.v27.i23.3182","article-title":"Silencing hepatitis B virus covalently closed circular DNA: the potential of an epigenetic therapy approach","volume":"27","author":"Singh","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s41048-020-00112-z","article-title":"Epigenetic regulation of covalently closed circular DNA minichromosome in hepatitis B virus infection","volume":"6","author":"Wang","year":"2020","journal-title":"Biophys Rep"},{"issue":"8","key":"10.1016\/j.aohep.2024.101533_bib0011","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3390\/jcm10081715","article-title":"Host Epigenetic alterations and hepatitis B virus-associated hepatocellular carcinoma","volume":"10","author":"Zeisel","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.aohep.2024.101533_bib0013","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/ph15121542","article-title":"Hepatitis B Therapeutic Vaccine: a Patent Review","volume":"15","author":"Hudu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.aohep.2024.101533_bib0014","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/vaccines9111333","article-title":"Improving therapeutic vaccination against hepatitis B\u2014insights from preclinical models of immune therapy against persistent hepatitis B virus infection","volume":"9","author":"Knolle","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.aohep.2024.101533_bib0015","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12072-018-9890-x","article-title":"Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study","volume":"12","author":"Lai","year":"2018","journal-title":"Hepatol Int"},{"issue":"9","key":"10.1016\/j.aohep.2024.101533_bib0016","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/infdis\/jiz607","article-title":"Single hepatocyte hepatitis B virus transcriptional landscape in HIV coinfection","volume":"221","author":"Balagopal","year":"2020","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0017","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jmoldx.2018.01.010","article-title":"A highly sensitive and robust method for hepatitis B virus covalently closed circular DNA detection in single cells and serum","volume":"20","author":"Huang","year":"2018","journal-title":"J Mol Diagn"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0018","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.21299","article-title":"Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients","volume":"44","author":"Laras","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0019","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/j.gastro.2007.06.057","article-title":"Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients","volume":"133","author":"Volz","year":"2007","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.aohep.2024.101533_bib0020","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","article-title":"Structural organization of the hepatitis B virus minichromosome","volume":"307","author":"Bock","year":"2001","journal-title":"J Mol Biol"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/v9060139","article-title":"Detection of HBV covalently closed circular DNA","volume":"9","author":"Li","year":"2017","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0023","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0024","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12929-020-00662-x","article-title":"HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice","volume":"27","author":"Horng","year":"2020","journal-title":"J Biomed Sci"},{"issue":"10","key":"10.1016\/j.aohep.2024.101533_bib0025","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/microorganisms8101470","article-title":"Impact of hepatitis B virus genetic variation, integration, and lymphotropism in antiviral treatment and oncogenesis","volume":"8","author":"Lau","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.aohep.2024.101533_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1128807","article-title":"The progress of molecules and strategies for the treatment of HBV infection","volume":"13","author":"Pan","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0027","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes and their antiviral effector functions","volume":"1","author":"Schoggins","year":"2011","journal-title":"Curr Opin Virol"},{"issue":"17","key":"10.1016\/j.aohep.2024.101533_bib0028","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0029","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","article-title":"Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: hBsAg loss is associated with HBV genotype","volume":"101","author":"Flink","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0031","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","article-title":"How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?","volume":"67","author":"Rajoriya","year":"2017","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2024.101533_bib0032","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jvh.13721","article-title":"Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: a 35,000-Korean outcome study","volume":"29","author":"Lim","year":"2022","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0033","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jmv.23567","article-title":"Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice","volume":"85","author":"Salpini","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.aohep.2024.101533_bib0034","first-page":"87","article-title":"Current perspectives on nucleos(t)ide analogue therapy for the long-term treatment of hepatitis B virus","volume":"14","author":"Broquetas","year":"2022","journal-title":"Hepat Med"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1021\/acsinfecdis.7b00144","article-title":"Discovery of small molecule therapeutics for treatment of chronic HBV infection","volume":"4","author":"Feng","year":"2018","journal-title":"ACS Infect Dis"},{"issue":"12","key":"10.1016\/j.aohep.2024.101533_bib0036","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0037","doi-asserted-by":"crossref","first-page":"e1232","DOI":"10.1002\/cti2.1232","article-title":"Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures","volume":"10","author":"Jansen","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"10","key":"10.1016\/j.aohep.2024.101533_bib0038","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/vaccines10101644","article-title":"Development of therapeutic vaccine for chronic hepatitis B: concept, cellular and molecular events, design, limitation, and future projection","volume":"10","author":"Akbar","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0039","doi-asserted-by":"crossref","first-page":"e00053","DOI":"10.1128\/MMBR.00053-21","article-title":"The baltimore classification of viruses 50 years later: how does it stand in the light of virus evolution?","volume":"85","author":"Koonin","year":"2021","journal-title":"Microbiol Mol Biol Rev"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0040","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2024.101533_bib0041","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"issue":"12","key":"10.1016\/j.aohep.2024.101533_bib0042","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1128\/JVI.02721-06","article-title":"Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein","volume":"81","author":"Gao","year":"2007","journal-title":"J Virol"},{"issue":"479\u2013480","key":"10.1016\/j.aohep.2024.101533_bib0043","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","author":"Seeger","year":"2015","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.aohep.2024.101533_bib0044","doi-asserted-by":"crossref","first-page":"e8093","DOI":"10.1371\/journal.pone.0008093","article-title":"Mechanism for CCC DNA synthesis in hepadnaviruses","volume":"4","author":"Sohn","year":"2009","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0045","doi-asserted-by":"crossref","first-page":"10478","DOI":"10.1038\/srep10478","article-title":"Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues","volume":"5","author":"Jain","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0046","doi-asserted-by":"crossref","first-page":"e56711","DOI":"10.1371\/journal.pone.0056711","article-title":"Comparative analysis of CpG Islands among HBV genotypes","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.aohep.2024.101533_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.aohep.2024.101533_bib0048","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-021-21850-9","article-title":"Hepatitis B virus cccDNA is formed through distinct repair processes of each strand","volume":"12","author":"Wei","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.aohep.2024.101533_bib0049","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.antiviral.2017.11.015","article-title":"The diverse functions of the hepatitis B core\/capsid protein (HBc) in the viral life cycle: implications for the development of HBc-targeting antivirals","volume":"149","author":"Diab","year":"2018","journal-title":"Antiviral Res"},{"issue":"10","key":"10.1016\/j.aohep.2024.101533_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001162","article-title":"Nuclear export and import of human hepatitis B virus capsid protein and particles","volume":"6","author":"Li","year":"2010","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.aohep.2024.101533_bib0051","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","article-title":"Restoring, releasing or replacing adaptive immunity in chronic hepatitis B","volume":"16","author":"Maini","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.aohep.2024.101533_bib0052","doi-asserted-by":"crossref","first-page":"338","DOI":"10.21037\/atm.2016.09.11","article-title":"Diagnosis of hepatitis B","volume":"4","author":"Song","year":"2016","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0053","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0054","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.gastro.2018.08.061","article-title":"Insights from antiviral therapy into immune responses to HBV and HCV infection","volume":"156","author":"Rehermann","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2024.101533_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coi.2015.06.016","article-title":"Host-virus interactions in hepatitis B virus infection","volume":"36","author":"Guidotti","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"6176","key":"10.1016\/j.aohep.2024.101533_bib0056","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0057","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0058","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2018.03.027","article-title":"Nonlytic lymphocytes engineered to express virus-specific T-cell receptors limit HBV infection by activating APOBEC3","volume":"155","author":"Koh","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.aohep.2024.101533_bib0059","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1074\/jbc.M008444200","article-title":"Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition *","volume":"276","author":"Alimonti","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.aohep.2024.101533_bib0060","series-title":"Handbook of proteolytic enzymes (Third edition)","first-page":"2718","article-title":"Chapter 598 - granzyme B","author":"Froelich","year":"2013"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0061","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1074-7613(03)00050-5","article-title":"Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors","volume":"18","author":"Sutton","year":"2003","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.aohep.2024.101533_bib0062","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1099\/vir.0.18966-0","article-title":"Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore\/core proteins","volume":"84","author":"Fern\u00e1ndez","year":"2003","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0063","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1101\/gad.479209","article-title":"A phosphorylation-acetylation switch regulates STAT1 signaling","volume":"23","author":"Kr\u00e4mer","year":"2009","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.aohep.2024.101533_bib0064","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/v11050427","article-title":"Human Hepatitis B Virus Core Protein Inhibits IFN\u03b1-Induced IFITM1 Expression by Interacting with BAF200","volume":"11","author":"Li","year":"2019","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.aohep.2024.101533_bib0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1089\/dna.2015.2933","article-title":"DeSUMOylation: an important therapeutic target and protein regulatory event","volume":"34","author":"Huang","year":"2015","journal-title":"DNA Cell Biol"},{"issue":"50","key":"10.1016\/j.aohep.2024.101533_bib0066","doi-asserted-by":"crossref","first-page":"20379","DOI":"10.1074\/jbc.M117.796839","article-title":"Host transcription factor Speckled 110 kDa (Sp110), a nuclear body protein, is hijacked by hepatitis B virus protein X for viral persistence","volume":"292","author":"Sengupta","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.aohep.2024.101533_bib0067","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.molimm.2020.04.024","article-title":"Hepatitis B virus X protein (HBx) promotes ST2 expression by GATA2 in liver cells","volume":"123","author":"Chen","year":"2020","journal-title":"Mol Immunol"},{"issue":"13","key":"10.1016\/j.aohep.2024.101533_bib0068","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1093\/nar\/gks281","article-title":"Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies","volume":"40","author":"Bresnick","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0069","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/liv.12530","article-title":"Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice","volume":"35","author":"Yoon","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0070","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1084\/jem.20162115","article-title":"IL-2high tissue-resident T cells in the human liver: sentinels for hepatotropic infection","volume":"214","author":"Pallett","year":"2017","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0071","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/biom12030470","article-title":"PD-L1 silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis B","volume":"12","author":"Bunse","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0072","doi-asserted-by":"crossref","first-page":"G162","DOI":"10.1152\/ajpgi.00197.2019","article-title":"Hepatitis B virus-triggered PTEN\/\u03b2-catenin\/c-Myc signaling enhances PD-L1 expression to promote immune evasion","volume":"318","author":"Sun","year":"2020","journal-title":"Am J Phys Gastrointest Liver Physiol"},{"issue":"7764","key":"10.1016\/j.aohep.2024.101533_bib0073","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"issue":"7764","key":"10.1016\/j.aohep.2024.101533_bib0074","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.aohep.2024.101533_bib0075","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI33402","article-title":"Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection","volume":"118","author":"Lopes","year":"2008","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.aohep.2024.101533_bib0076","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0077","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2024.101533_bib0078","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coviro.2015.10.008","article-title":"Roles of natural killer cells in antiviral immunity","volume":"16","author":"Waggoner","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"16","key":"10.1016\/j.aohep.2024.101533_bib0079","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1128\/JVI.76.16.8124-8137.2002","article-title":"Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein","volume":"76","author":"Daub","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.aohep.2024.101533_bib0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antiviral Res"},{"issue":"5","key":"10.1016\/j.aohep.2024.101533_bib0081","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1128\/JVI.03235-13","article-title":"Nucleic acid chaperone activity associated with the arginine-rich domain of human hepatitis B virus core protein","volume":"88","author":"Chu","year":"2014","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0082","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/epi.6.6.15815","article-title":"HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state","volume":"6","author":"Guo","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.aohep.2024.101533_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.05.003","article-title":"Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome","volume":"144","author":"Chong","year":"2017","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0084","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1139\/o02-133","article-title":"Hepatitis B viral core protein activates the hepatitis B viral enhancer II\/pregenomic promoter through the nuclear factor kappaB binding site","volume":"80","author":"Kwon","year":"2002","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.aohep.2024.101533_bib0085","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s005350170027","article-title":"Hepatitis B virus X protein: a multifunctional viral regulator","volume":"36","author":"Murakami","year":"2001","journal-title":"J Gastroenterol"},{"issue":"26","key":"10.1016\/j.aohep.2024.101533_bib0086","doi-asserted-by":"crossref","first-page":"9555","DOI":"10.1073\/pnas.1400604111","article-title":"HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators","volume":"111","author":"Lee","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.aohep.2024.101533_bib0087","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.aohep.2024.101533_bib0088","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110442","article-title":"Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0089","doi-asserted-by":"crossref","first-page":"e01840","DOI":"10.1128\/jvi.01840-18","article-title":"Parvulin 14 and parvulin 17 bind to HBx and cccDNA and upregulate hepatitis B virus replication from cccDNA to virion in an HBx-dependent manner","volume":"93","author":"Saeed","year":"2019","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0090","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/hep.29912","article-title":"SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases","volume":"68","author":"Ren","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.aohep.2024.101533_bib0091","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/JVI.02574-12","article-title":"Methyltransferase PRMT1 is a binding partner of hbx and a negative regulator of hepatitis B virus transcription","volume":"87","author":"Benhenda","year":"2013","journal-title":"J Virol"},{"issue":"24","key":"10.1016\/j.aohep.2024.101533_bib0092","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.18632\/oncotarget.28077","article-title":"Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma","volume":"12","author":"Medhat","year":"2021","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0093","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1515\/BC.2003.022","article-title":"Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells","volume":"384","author":"Kwon","year":"2003","journal-title":"Biol Chem"},{"issue":"6","key":"10.1016\/j.aohep.2024.101533_bib0094","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1096\/fj.02-0431rev","article-title":"Evolving intricacies and implications of E2F1 regulation","volume":"17","author":"Mundle","year":"2003","journal-title":"The Faseb Journal"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0095","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cancers3010994","article-title":"Role of p53 in cell death and human cancers","volume":"3","author":"Ozaki","year":"2011","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0096","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-014-0498-3","article-title":"Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer","volume":"17","author":"Harris","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0097","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1053\/j.gastro.2007.01.034","article-title":"Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein","volume":"132","author":"Park","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0098","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3892\/mmr.2015.4545","article-title":"Hepatitis B virus X protein upregulates DNA methyltransferase 3A\/3B and enhances SOCS-1CpG island methylation","volume":"13","author":"Fu","year":"2016","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0099","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3892\/or.2013.2848","article-title":"Upregulation of DNMT1 mediated by HBx suppresses RASSF1A expression independent of DNA methylation","volume":"31","author":"Qiu","year":"2014","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10238-012-0182-9","article-title":"Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression","volume":"13","author":"Fang","year":"2013","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.aohep.2024.101533_bib0101","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/onc.2011.255","article-title":"Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer","volume":"31","author":"Arzumanyan","year":"2012","journal-title":"Oncogene"},{"issue":"51","key":"10.1016\/j.aohep.2024.101533_bib0102","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"25","author":"Vandepapeli\u00e8re","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0103","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jmv.24091","article-title":"The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection","volume":"87","author":"Lee","year":"2015","journal-title":"J Med Virol"},{"issue":"51","key":"10.1016\/j.aohep.2024.101533_bib0104","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1016\/j.vaccine.2010.09.093","article-title":"Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine","volume":"28","author":"Wang","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2024.101533_bib0106","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","article-title":"Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B","volume":"15","author":"Wang","year":"2020","journal-title":"Nat Nanotechnol"},{"issue":"20","key":"10.1016\/j.aohep.2024.101533_bib0107","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.01184-15","article-title":"Virus-like vesicle-based therapeutic vaccine vectors for chronic hepatitis B virus infection","volume":"89","author":"Reynolds","year":"2015","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0108","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial\u2014ANRS HB02 VAC-ADN","volume":"64","author":"Fontaine","year":"2015","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0109","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3748\/wjg.v23.i2.306","article-title":"Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy","volume":"23","author":"Yang","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0110","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01612-22","article-title":"A single dose of Anti-HBsAg antibody-encoding mRNA-LNPs suppressed HBsAg expression: a potential cure of chronic hepatitis B virus infection","volume":"13","author":"Chen","year":"2022","journal-title":"MBio"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0111","doi-asserted-by":"crossref","first-page":"e14626","DOI":"10.1371\/journal.pone.0014626","article-title":"Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection","volume":"6","author":"Cavenaugh","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.aohep.2024.101533_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.fmre.2023.02.022","article-title":"mRNA therapeutics: new vaccination and beyond","author":"Wei","year":"2023","journal-title":"Fundamental Res."},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/vaccines10010045","article-title":"The safety and efficacy of a therapeutic vaccine for chronic hepatitis B: a follow-up study of phase III clinical trial","volume":"10","author":"Akbar","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.aohep.2024.101533_bib0114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201236","article-title":"Treatment of chronic hepatitis B na\u00efve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)","volume":"13","author":"Al Mahtab","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.aohep.2024.101533_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(11)60753-8","article-title":"Treatment of chronic hepatitis B infection with DV601, a therapeutic vaccine","volume":"54","author":"Spellman","year":"2011","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0116","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S0618-8278(19)30090-8","article-title":"A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection","volume":"70","author":"Lim","year":"2019","journal-title":"J Hepatol"},{"issue":"13","key":"10.1016\/j.aohep.2024.101533_bib0117","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.vaccine.2010.01.038","article-title":"Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers","volume":"28","author":"Luo","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0118","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.intimp.2015.06.019","article-title":"Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection","volume":"27","author":"Wei","year":"2015","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101533_bib0119","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2024.101533_bib0121","series-title":"Hepatitis b fact sheet","year":"2023"},{"key":"10.1016\/j.aohep.2024.101533_bib0122","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.aohep.2024.101533_bib0123","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3748\/wjg.v22.i4.1497","article-title":"Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma","volume":"22","author":"Sukowati","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101533_bib0124","first-page":"258","article-title":"HBV cccDNA and its potential as a therapeutic target","volume":"7","author":"Zhu","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.aohep.2024.101533_bib0125","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1038\/emi.2017.41","article-title":"Differences in sequences between HBV-relaxed circular DNA and covalently closed circular DNA","volume":"6","author":"Rybicka","year":"2017","journal-title":"Emerg Microbes Infect"},{"issue":"5","key":"10.1016\/j.aohep.2024.101533_bib0126","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4254\/wjh.v14.i5.866","article-title":"Role of hepatitis B virus in development of hepatocellular carcinoma: focus on covalently closed circular DNA","volume":"14","author":"Bianca","year":"2022","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101533_bib0127","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.aohep.2024.101533_bib0128","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/mt.2016.94","article-title":"Complete spectrum of CRISPR\/Cas9-induced mutations on HBV cccDNA","volume":"24","author":"Seeger","year":"2016","journal-title":"Mol Ther"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124003272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124003272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:39:58Z","timestamp":1778621998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268124003272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1665268124003272"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101533","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101533"}}